Clinical Trial

Related by string. clinical trials * clinicals : Phase III clinical trials / trial : Week Premium Trial * Phase III Clinical Trial . placebo controlled clinical trials . randomized clinical trials . randomized controlled clinical trials . clinical pharmacology clinical trials . IIa clinical trial . Phase IIa clinical trials . Clinical Trial Results . Clinical Trial Application *

Related by context. All words. (Click for frequent words.) 78 Clinical Study 75 Clinical Trials 74 Phase III Clinical Trial 74 Phase III Trial 71 Clinical Trial Results 70 Pivotal Trial 70 II Clinical Trial 69 Phase IIb Trial 69 Phase 2b Clinical Trial 69 Phase IIb Clinical Trial 69 Patient Enrollment 68 Pivotal Study 68 Completes Enrollment 68 Clinical Trial Evaluating 68 Drug Candidate 67 Phase 2a Trial 67 Completes Patient Enrollment 67 Pivotal Phase 67 Phase 2b Study 67 Meets Primary Endpoint 67 clinical trial 67 Study Evaluating 66 Initiate Phase 66 Receives Orphan Drug Designation 66 Pivotal Phase III 65 Phase IIa Clinical Trial 65 Combination Treatment 65 Pivotal Trials 65 Successfully Completes Phase 64 Phase III Pivotal 64 Lung Cancer Trial 64 Phase 1b Clinical Trial 64 Prolongs Survival 64 Phase 2b Trial 64 Clinical Evaluation 64 Clinical 64 Preclinical Data 64 Improves Survival 64 Prospective Randomized 64 Pulmonary Arterial Hypertension 64 Clinical Research 64 Trial Evaluating 64 IIa Clinical Trial 64 Combination REOLYSIN R 64 Phase III Trials 64 IND Filing 64 FDA Accepts 64 FDA Approval 64 Pivotal Clinical Trial 64 Initiate Clinical Trial 64 Patients Treated With 64 Patient Enrolment 63 Previously Treated 63 Phase III Clinical Trials 63 Initiates Clinical 63 Therapy Evaluation 63 Long Term Efficacy 63 Phase IIIb 63 Investigational Drug 63 Patients Enrolled 63 Phase 2a Clinical Trial 63 Randomized Controlled 63 Diabetic Patients 63 Presents Positive 63 Presents Preclinical Data 63 Confirmatory Phase 63 Initiates Phase III 63 JAK2 Inhibitor 63 Prostate Cancer Vaccine 63 Investigational Agent 63 Files IND 63 Receives Positive Opinion 63 Present Preclinical Data 63 Autologous Stem Cell Transplantation 63 Patients Suffering 62 Single Dose 62 Patent Covering 62 Hepatocellular Carcinoma 62 Demonstrates Positive 62 Inhaled Insulin 62 Initiates Phase II 62 Initiates Clinical Trial 62 Advanced Melanoma 62 Oral Fingolimod 62 Treatment Resistant 62 Investigational Compound 62 First Patient Dosed 62 Pharmacokinetic Study 62 Initiates Phase 62 clinical trials 62 Prostate Cancer Treatment 62 Overactive Bladder 62 Efficacy Trial 62 Investigational Treatment 62 Stem Cell Treatment 62 Novel Oral 62 Patients Treated 62 First Patient Treated 62 Anti Tumor Activity 62 Drug Eluting Stent 62 Non Invasive 62 Immunotherapeutic 62 Cutaneous T 62 Expanded Indication 62 First Patient Enrolled 62 Severe Sepsis 62 Protease Inhibitor 62 Lupus Drug 62 Initiates Clinical Trials 62 Metastatic Melanoma 62 Clinical Efficacy 62 NDA Submission 62 Multicenter Randomized 62 Dose Ranging Study 62 Heart Failure Patients 62 Monoclonal Antibody 62 Improves Outcomes 62 Subgroup Analysis 61 Improve Survival 61 FDA Approves 61 Small Molecule 61 JAK Inhibitor 61 Vaccine Trial 61 Adjunctive Therapy 61 Dose Escalation 61 Granted Orphan Drug 61 Drug Shows Promise 61 Well Tolerated 61 Myelodysplastic Syndromes 61 Hsp# Inhibitor 61 Shows Efficacy 61 Interferon Alpha 61 Adjuvant Treatment 61 Acute Myocardial Infarction 61 IND Application 61 Study Showed 61 HCV Protease Inhibitor 61 Clinical Trial Data 61 Antitumor Activity 61 Commence Phase 61 Randomized Phase 61 Completes Patient Enrolment 61 Treatment Naive Patients 61 Shows Promising 61 Demonstrates Significant 61 Therapeutic Vaccine 61 Fast Track Status 61 Advanced Prostate Cancer 61 Malaria Vaccine 61 Vaccine Trials 61 Clinical Outcome 61 Receives Milestone Payment 61 Phase III Pivotal Trial 61 Rheumatoid Arthritis Patients 61 Pneumococcal Vaccine 61 Acute Ischemic Stroke 61 Initiates Enrollment 61 Initiate Phase II 60 Randomized Study 60 Patient Recruitment 60 RNAi Therapeutics 60 Kinase Inhibitor 60 Venous Thromboembolism 60 Randomized Double Blind 60 Chronic Heart Failure 60 Initiates Phase 2b 60 Solid Tumors 60 Cardiovascular Outcomes 60 Begin Clinical Trials 60 Dose Escalation Study 60 Infected Patients 60 Molecular Diagnostic Test 60 Postmenopausal Women 60 Intravenous Formulation 60 Randomized Clinical Trial 60 Multicenter 60 Topline Results 60 Prostate Cancer Patients 60 Seasonal Influenza Vaccine 60 Systemic Delivery 60 IIa clinical 60 Hematologic Malignancies 60 Arthritis Drug 60 Metastatic Colorectal Cancer 60 Lung Cancer Drug 60 Renal Cancer 60 Disease Modifying 60 Monotherapy 60 Relapsing Multiple Sclerosis 60 Multiple Myeloma Patients 60 Initiated Phase 60 Metastatic Prostate Cancer 60 Receives Orphan Drug 60 RNAi Therapeutic 60 Platelet Inhibition 60 Disease Progression 60 Controlled Study 60 Osteoarthritis Patients 60 Pooled Analysis 60 Receives FDA Clearance 60 Vaccine Adjuvant 60 Oral Calcitonin 60 Randomized Phase II 60 Demonstrates Sustained 60 Inhaled Liposomal Ciprofloxacin 60 Phase Ib clinical 60 FDA Clears 60 Tuberculosis Vaccine 60 Significantly Improves 60 Surgical Mesh 60 Phase IIb 60 Smallpox Vaccine 60 Positive Opinion 60 Rheumatoid Arthritis Drug 60 Universal Flu Vaccine 60 Anticancer Activity 60 Avian Flu Vaccine 60 Phase III clinical 60 Relapsed Multiple Myeloma 60 Patient Outcomes 59 phase IIa 59 Osteoporosis Drug 59 FDA Clearance 59 Proves Effective 59 Biomarker Study 59 Inflammatory Arthritis 59 Treatment Naive 59 Preclinical Models 59 Chronic Hepatitis B 59 Survival Benefit 59 Hematological Cancers 59 Submits NDA 59 Oral Interferon 59 Systemic Sclerosis 59 Renal Cell Carcinoma 59 Hormone Refractory Prostate Cancer 59 Hepatitis C Virus 59 Phase IIIb study 59 LUMINATE 59 Epilepsy Drug 59 Pivotal Phase II 59 Advanced Renal Cell 59 Initiate Phase III 59 Clinical Validation 59 Cancer Treatments 59 Sapacitabine 59 Advanced Pancreatic Cancer 59 Resistant Hypertension 59 Shows Promise Against 59 Chronic Hepatitis C 59 SUTENT ® 59 Phase III multicenter 59 Complicated Skin 59 Anticancer Drug 59 Demonstrates Potent 59 Pandemic Influenza Vaccine 59 Announces FDA Clearance 59 ISTODAX ® 59 Chronic Lymphocytic Leukemia 59 Prospective Multicenter 59 Therapeutic Antibody 59 Diabetic Nephropathy 59 Ischemic Stroke 59 Adjuvant Chemotherapy 59 Antiepileptic Drug 59 Schizophrenia Drug 59 Fungal Infections 59 Acute Decompensated Heart Failure 59 Combination Therapy 59 Oral Cladribine 59 Cancer Vaccine 59 Treating Chronic 59 Osteoporosis Treatment 59 Benign Prostatic Hyperplasia 59 Investigational 59 Preclinical Study 59 Enrolling Patients 59 Multicenter Study 59 Orphan Status 59 Milestone Payment 59 Stem Cell Transplant 59 Elderly Patients 59 Metabolic Disease 59 Smooth Muscle 59 Gout Drug 59 FDA Approvals 59 Tissue Repair 59 Newly Diagnosed Multiple Myeloma 59 Soft Tissue Sarcoma 59 Transdermal Patch 59 Feasibility Trial 59 Romidepsin 59 Tumor Targeting 59 Gastric Cancer 59 Maven Semantic 59 Appears Safe 59 Psoriasis Drug 59 Regenerative Cells 59 Novel Antibiotic 59 Anticoagulation 59 Advanced Colorectal Cancer 59 Treating Heart Failure 58 Dupuytren Contracture 58 Mouse Model 58 Topical Treatment 58 Orphan Drug Status 58 Synta Announces 58 Elagolix 58 Hypercholesterolemia 58 Phase III Psoriasis 58 Recurrent Prostate Cancer 58 Liver Cancer 58 Gene Therapy Trial 58 Reperfusion Injury 58 FOLOTYN ® 58 Glatiramer Acetate 58 Presents Positive Preclinical 58 Adjuvant Therapy 58 Diabetic Foot Ulcer 58 R lenalidomide 58 Receives Marketing Authorization 58 Balloon Angioplasty 58 Sustained Efficacy 58 Randomized Double Blind Placebo 58 Anti Angiogenesis 58 Is Well Tolerated 58 Treatment Regimen 58 ENDEAVOR IV 58 Minimally Invasive Treatment 58 Achieves Primary Endpoint 58 Fabry Disease 58 Antiviral Activity 58 IL# PE#QQR 58 Phase IIa 58 Recombinant Human 58 Nymox NX 58 Epidemiological Studies Unit 58 Earns Milestone Payment 58 Observational Study 58 Phase IIIb clinical 58 Neoadjuvant Chemotherapy 58 Pafuramidine 58 Meta Analysis 58 Multicenter Trial 58 Randomized Clinical Trials 58 Phase Ib 58 Significantly Reduces 58 Demonstrates Ability 58 Demonstrates Efficacy 58 Metabolic Disorder 58 Drug Eluting 58 Placebo Controlled Trial 58 Receives Approvable Letter 58 Dual Antiplatelet Therapy 58 Influenza Vaccine 58 Aneurysm Repair 58 Autoimmune Disease 58 Early Diagnosis 58 Carboplatin Paclitaxel 58 Bladder Cancer 58 Phase III 58 Patients Undergoing 58 Improved Survival 58 phase Ib 58 Anti Tumor 58 Breast Cancer Treatment 58 Acute Pain 58 Patients Receiving 58 FDA Okays 58 Preclinical Efficacy 58 See CLINICAL PHARMACOLOGY 58 Myocardial Infarction 58 Develop Novel 58 Phase Ib Clinical Trial 58 Drug Eluting Stents 58 Potent Antiviral Activity 58 Phase Ib II 58 NICE Recommends 58 Autoimmune Diseases 58 Drug Fails 58 Rotary VAD 58 Adverse Event 58 Drug Eluting Stent System 58 Desvenlafaxine Succinate 58 HDAC Inhibitor 58 Microplasmin 58 Study Demonstrates 58 Lung Cancer Patients 58 Treated Patients 58 Initiates Dosing 57 Prophylactic Treatment 57 Statin Therapy 57 Files Investigational 57 Rotavirus Vaccine 57 Predict Risk 57 Antibody Drug Conjugate 57 Polymerase Inhibitor 57 Anti Inflammatory Drug 57 Ozarelix 57 Diagnostic Tests 57 Randomized Double blind 57 Acute Coronary Syndromes 57 Augment TM 57 Emerging Therapies 57 Investigational Oral 57 Personalized Immunotherapy 57 Randomized Evaluation 57 Relapsed Refractory 57 Sipuleucel T 57 Novel Inhibitor 57 Unstable Angina 57 Randomized Controlled Trials 57 number NCT# ClinicalTrials.gov 57 Eluting Stent 57 Less Invasive 57 Successfully Treated 57 Endovascular Treatment 57 Rheumatoid Arthritis 57 Hepatitis B Vaccine 57 Treatment Naïve 57 Implantable Device 57 Therapeutic Efficacy 57 Blood Pressure Drug 57 Mylan Receives Approval 57 Gastrointestinal Cancers 57 Antiviral Therapy 57 Demonstrates Potential 57 Newly Diagnosed 57 Drug Eluting Coronary Stent 57 ID NCT# 57 Oral Mucositis 57 Vascular Disrupting Agent 57 Therapeutic Antibodies 57 Drug Resistant 57 Tumor Response 57 Brentuximab Vedotin SGN 57 Non Inferiority 57 Treatment Reduces 57 Interferon Beta 57 Hospitalized Patients 57 Antibody Discovery 57 Cell Transplant 57 Post Operative 57 Embolization 57 Peginterferon Alfa 2b 57 Bird Flu Vaccine 57 Recombinant Protein 57 Confirms Efficacy 57 TM Drug Eluting 57 Weight Loss Drug 57 Hematological Malignancies 57 Anticoagulant 57 Versus Placebo 57 Immune Mediated 57 Improve Outcomes 57 Immunosuppression 57 KRN# 57 TB Vaccine 57 Treatment Experienced 57 Low Dose 57 Receives Complete Response 57 Unresectable 57 Schizophrenia Treatment 57 Inhibits Growth 57 Regenerative Cell 57 Bone Metastases 57 Receives CE Marking 57 Stem Cell Transplants 57 Cholesterol Drug 57 signal detection CTSD 57 Kidney Function 57 Novel Therapeutic 57 Advanced Heart Failure 57 Clinical Outcomes 57 Testosterone MDTS ® 57 Kidney Transplant Patients 57 Cloretazine ® 57 Cancer Immunotherapy 57 Endeavor Drug Eluting 57 Heart Transplant Recipients 57 Nicotine Vaccine 57 Gets FDA Clearance 57 Novel Compound 57 Tyrosine Kinase Inhibitor 57 Guidelines Issued 57 Phase 1b trial 57 Phase IIb III 57 Metastatic Renal Cell Carcinoma 57 Carotid Stenting 57 Aryplase 57 FDA Approves Drug 57 Hemodialysis Patients 57 Adverse Outcomes 57 Pharmaceuticals Initiates 57 multicenter prospective 57 Oral Insulin Capsule 57 Zenvia Phase III 57 Artificial Pancreas 57 ThermoDox R 57 Diabetic Retinopathy 57 Statistically Significant 57 Phase IIa trial 57 Diabetic Ulcers 57 Luveniq 57 Radiation Treatment 57 Breast Cancer Recurrence 57 Double Blind Placebo 57 Tesamorelin 57 Randomized Trials 57 Blood Thinner 57 Diabetic Neuropathy 57 Genes Involved 57 Reveals Positive 57 Estrogen Therapy 57 Pharmacogenomic 57 Erythropoietic 57 Immunosuppressant 57 Generic Version 57 Begins Clinical Trial 57 Atopic Dermatitis 57 TRANSDUR ™ 56 Receptor Agonist 56 Controlled Trial 56 Partial Onset Seizures 56 Laryngeal Cancer 56 Reports Preclinical Data 56 Antiplatelet 56 Mycophenolate Mofetil 56 pharmacogenomic translational research 56 Total Knee Arthroplasty 56 Anti CD# Antibody 56 Risk Stratification 56 Cardiac Resynchronization Therapy 56 Antisense Drug 56 Contrast Agent 56 Sangamo BioSciences Announces 56 Lung Injury 56 Cancer Therapies 56 Collaborators Publish 56 Safinamide 56 Multicenter Phase 56 ARIXTRA R 56 Spectrum Pharmaceuticals Announces 56 Antiplatelet Therapy 56 Humanized Anti 56 Commences Phase 56 Cell Transplants 56 Preclinical 56 Prostate Biopsy 56 Virus Infection 56 Recurrent Breast Cancer 56 Omacetaxine 56 Postmenopausal Osteoporosis 56 Surgical Treatment 56 Castration Resistant Prostate Cancer 56 Oral Insulin 56 Max Neeman International 56 Unfractionated Heparin 56 Cholesterol Lowering Drug 56 Immunomedics Announces 56 Phase 2b trial 56 Significantly Improved 56 Coronary Revascularization 56 Anticancer Agent 56 Study Validates 56 Surgical Procedures 56 Announces Positive 56 Phase 2a clinical 56 Hepatitis C Genotype 56 Inhaled Nitric Oxide 56 Previously Untreated 56 Renal Artery 56 Tumor Growth 56 Clinical Study Shows 56 Phase 1b clinical 56 Novel Small Molecule 56 Successfully Treats 56 Early Relapsing Multiple 56 Vaccine Candidate 56 DIRECT Trial 56 Slow Progression 56 Biomarker 56 Therapeutic Potential 56 Blood Pressure Lowering 56 Refractory Angina 56 Endovascular Valve Edge 56 Immunogenicity 56 Plaque Psoriasis 56 Cardiac Rhythm 56 Node Positive 56 Progenitor Cells 56 Phase IIa Trial 56 Insulin Resistance 56 Tolerability 56 Heart Failure Treatment 56 Allergic Rhinitis 56 Chronic Renal Failure 56 Naive Patients 56 ENESTnd 56 multicenter multinational 56 Showed Significant 56 Renin Inhibitor 56 Collaborators Present 56 Receives Fast Track 56 Critical Limb Ischemia 56 Ofatumumab 56 Study Evaluates 56 Treatment Shows Promise 56 Abdominal Stent Graft 56 Treat Anemia 56 Teva Provides Update 56 Immune Cell 56 Preclinical Studies 56 Fondaparinux 56 Spinal Fusion 56 Breast Cancer Patients 56 EVIZON TM 56 Severe Asthma 56 Phase IIb trial 56 Cervical Cancer Vaccine 56 Novel Mechanism 56 Lowers Risk 56 Taro Receives 56 Acute Treatment 56 phase IIa clinical 56 HER2 Positive Breast Cancer 56 Ocrelizumab 56 Hormone Receptor Positive 56 Renal Transplantation 56 Bucindolol 56 Neuroendocrine Tumors 56 BiTE Antibody 56 Anemia Drug 56 WorldHeart Announces 56 Replacement Therapy 56 Diamyd Medical Diamyd 56 Begins Dosing 56 Uterine Fibroid Embolization 56 Multiple Ascending Dose 56 Submits IND 56 VIVUS Announces 56 Receives SFDA Approval 56 Embolic Protection 56 Submits Response 56 Hemorrhagic Stroke 56 Submits Biologics License Application 56 APEX PD 56 Ovarian Cancer Patients 56 Bazedoxifene 56 Active Rheumatoid Arthritis 56 NABTT 56 Hypertensive Patients 56 Diabetic Macular Edema 56 Patent Issued 56 Dose Response 56 Acute Attacks 56 Acute Heart Failure 56 SPIRIT III 56 Anti Clotting Drug 56 Small Vessel 56 Nuclear Receptors 56 Vascular Inflammation 56 Enzyme Replacement Therapy 56 Biopharmaceutical Industry 56 Neuroprotection 56 Cell Lymphoma 56 StaphVAX R 56 Marketing Authorisation Application 56 Inhalation Solution 56 Shingles Vaccine 56 Aurora Kinase 56 Targeted Therapy 56 Carotid Stent 56 Phase Ib study 56 Randomized Phase III 56 dependent kinase inhibitor 56 Vascular Targeting Agents 56 Bipolar Depression 56 Phase Ib IIa 56 Innate Immune 56 Congestive Heart Failure 56 Pediatric Patients 56 placebo controlled Phase III 56 Announces Poster Presentations 56 Tesetaxel 56 Percutaneous Tibial Nerve Stimulation 56 Osteoarthritis Pain 56 Generic Versions 56 PROMUS R 56 Clinical Trial Enrollment 56 Image Guided 56 Clinically Significant 56 Rotavirus Vaccines 56 Cardiovascular Events 56 Radical Prostatectomy 56 Experimental Vaccine 56 Blinatumomab 56 Left Ventricular Dysfunction 56 Gaucher Disease 56 Cardiometabolic 55 Melphalan 55 Tezampanel 55 Protein Linked 55 Reports Positive 55 Novolimus 55 Preclinical Testing 55 Recurrent Glioblastoma 55 AVI BioPharma Announces 55 Commercialize 55 Demonstrated Significant 55 PRN FDA Approves 55 Androgen Deprivation Therapy 55 REG2 55 Relapsing Remitting Multiple Sclerosis 55 HER2 Positive 55 Contrast Echocardiography 55 Medullary Thyroid Cancer 55 Efficacious 55 Targeted Therapies 55 Organ Rejection 55 Gene Mutation 55 Dry Powder Inhaler 55 XIENCE V Stent System 55 Protein Expression 55 C1 Inhibitor 55 Slows Progression 55 Resubmission 55 Chronic Sinusitis 55 Invasive Fungal Infections 55 Advanced Ovarian Cancer 55 MEK Inhibitor 55 Presents Preclinical 55 Obese Patients 55 VIVITROL ® 55 Bosutinib 55 pralatrexate injection folate analogue 55 Monoclonal Antibodies 55 Shows Promise 55 Nilotinib 55 Gentium Announces 55 Chronic Constipation 55 Phase 1b 55 Urinary Incontinence 55 Hepatitis C Treatment 55 Vicriviroc 55 Endurant 55 Tissue Engineered 55 Medidur TM FA 55 Dialysis Patients 55 VIVUS Qnexa 55 multicenter phase 55 Sustained Reduction 55 Combo Therapy 55 Medicure Announces 55 Hormone Therapy 55 Commercialize Novel 55 dose escalation clinical 55 Radiofrequency Ablation 55 relapsing multiple sclerosis 55 Cord Blood Banking 55 Genetic Tests 55 Artificial Cornea 55 Insulin Delivery 55 Receives CE 55 Artery Disease 55 Genes Linked 55 Cellular Immunotherapy 55 Therapeutic Targets 55 Trodusquemine MSI 55 Transdermal System 55 Trastuzumab DM1 55 Heart Transplantation 55 Nuvelo Announces 55 Treatment Approaches 55 Contrast Agents 55 Testosterone Gel 55 Sirolimus Eluting Stent 55 Asthma Treatment 55 albiglutide 55 Obtains CE Mark 55 Edge STudy 55 Vaccine Shows Promise 55 Phase 1a clinical 55 TAXUS ATLAS 55 Licenses Novel 55 Effectively Treats 55 CNS Therapeutics 55 Therapy Improves 55 initiated Phase Ib 55 Myeloma Patients 55 Eculizumab 55 Phase III HEAT 55 Genetic Testing 55 Combination Clinical Trial 55 Enrolls First 55 Chronic Myeloid Leukemia 55 Erectile Dysfunction Drug 55 Angiogenic 55 phase IIb 55 k Clearance 55 Intravitreal 55 Surgery Performed 55 Suicidality 55 Respiratory Virus 55 PDUFA Date 55 Commences Phase III 55 Ischemic 55 multicenter Phase 55 Molecular Diagnostic 55 Neurodegenerative Disease 55 Genetic Predisposition 55 Colorectal Cancer Patients 55 Dose Finding 55 Solid Malignancies 55 Dose Ranging 55 ST Elevation Myocardial 55 Significantly Reduced 55 Drug Combo 55 Non Invasive Treatment 55 Randomised 55 BrainGate TM 55 Glaucoma Treatment 55 Announces Publication 55 Phase 2a Study 55 Contrast Enhanced 55 Toxicogenomics 55 Multicentre 55 Genes Predict 55 Pathogenesis 55 phase IIb clinical 55 Amrubicin 55 Phase 2b study 55 evaluating mipomersen 55 Daclizumab 55 Pharmacokinetics PK 55 Proven Effective 55 Phase 1a 55 Breast Ultrasound 55 Novel Treatments 55 EVEREST II 55 Simulect 55 Peripheral Arterial Disease 55 Archexin 55 Long Term Outcomes 55 Radiation Induced 55 Electrophysiology Mapping 55 Bone Marrow Transplants 55 Cervical Dysplasia 55 ORENCIA ® 55 Skeletal Muscle 55 Treatment Naïve Patients 55 Chronic Lymphocytic Leukemia CLL 55 Milestone Payment From 55 Phase 2b clinical 55 Therapy Shows Promise 55 Vascular Grafts 55 Cypher Sirolimus 55 Symptom Relief 55 Stent Implantation 55 Pharmacyclics Announces 55 OLpur TM H2H 55 Phase IIB 55 Atypical Antipsychotic 55 Oncolytic 55 Enlarged Prostate 55 Kidney Transplants 55 Anticancer Compound 55 Protease Inhibitors 55 Androgen Independent 55 Exherin 55 Receives Patent 55 Submits Application 55 Liver Toxicity 55 Insulin Pen 55 Novel Therapies 55 Exemption IDE approval 55 Antipsychotic 55 Migraine Drug 55 Neoadjuvant 55 atypical Hemolytic Uremic Syndrome 55 Myocardial Ischemia 55 Peripheral Artery Disease 55 Inflammatory Diseases 55 Randomized Controlled Trial 55 Phase #b/#a clinical 55 Endothelial Cells 55 Prognostic Value 55 Systemic Lupus Erythematosus SLE 55 pharmacokinetic PK study 55 Lung Cancer Survival 55 Data Suggest 55 Transdermal Delivery 55 Virtual Colonoscopy 55 Efficacy Results 55 Hepatic Encephalopathy 55 Sign Licensing Agreement 55 Phase IIA 55 Phase #b/#a 55 Announces Presentation 55 Cardiotoxicity 55 Bone Graft 55 Stent Restenosis 55 Researchers Identify 55 TG MV 55 Companion Diagnostic 55 Decompensated Heart Failure 55 Denufosol 55 Vitrasert R 55 Brain Metastases 54 Ophthalmic Drug 54 Circulatory Support 54 HPV Vaccine Gardasil 54 multicenter Phase II 54 Telaprevir VX 54 Attenuates 54 Cognitive Problems 54 Protein Therapeutics 54 Current Controlled Trials 54 Postoperative Ileus 54 Circulating Tumor Cells 54 Files Patent Application 54 Knee Osteoarthritis 54 Flu Vaccines 54 comparing alemtuzumab 54 topically applied SEPA 54 Interferon Gamma 54 PHASE III 54 generation PNP inhibitor 54 AIR2 Trial 54 BioElectronics Announces 54 Adjuvant 54 Cell Lung Cancer 54 Cognitive Impairment 54 Ceflatonin R 54 Eluting 54 Advanced Gastric Cancer 54 Adverse Effects 54 MKC# MKC# PP 54 controlled dose escalation 54 Diabetic Neuropathic Pain 54 Clinical Trial Investigating REOLYSIN 54 Randomized Placebo controlled 54 Liver Metastases 54 Embolic 54 BioElectronics Corporation Announces 54 BioSante Pharmaceuticals Announces 54 Ebola Vaccine 54 PROVENGE ® 54 Pancreatic Adenocarcinoma 54 Phase III clinical trials 54 Interventional Procedures 54 STELARA TM 54 Interferon Alfa 54 Exclusive License 54 Cardiac Resynchronization 54 TO AVOID PREGNANCY WHILE 54 HCV SPRINT 54 Glucose Monitoring 54 Mitral Valve Repair 54 Synthetic Peptide 54 Aortic Valve 54 Hepatitis C Virus HCV 54 Factor Xa Inhibitor 54 Liberte TM 54 Japanese Encephalitis Vaccine 54 Neuroprotective Effects 54 Ranolazine 54 dirucotide MBP# 54 Entereg TM 54 Fast Track Designation 54 Integrase Inhibitor 54 Immunologic 54 Malignant Melanoma 54 Beta Blocker 54 Radiofrequency Ablation RFA 54 Inflammatory Markers 54 FDA Panel Recommends 54 Drug Coated Stents 54 REVEAL Registry 54 Drug Metabolism 54 DAPT Study 54 Phase Ib clinical trials 54 Treating Prostate Cancer 54 Acute Stroke 54 Medtronic CoreValve ® 54 Late Breaker 54 Advanced Solid Tumors 54 Investigator Initiated 54 Circ Pharma 54 Breast Tumor 54 Cancer Biomarker 54 Patient Accrual 54 Stent Thrombosis 54 Immunotherapies 54 Onyx Pharmaceuticals Announces 54 Inhibits 54 Efficacy Study 54 Systemic Lupus Erythematosus 54 Milestone Payments

Back to home page